Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endometrial pathology and estrogens.

Z Rosenwaks, A C Wentz, G S Jones

    Obstetrics and Gynecology
    |April 1, 1979
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Attitudes of adult 46, XY intersex persons to clinical management policies.

    The Journal of urology·2004
    Same author

    Gender assignment in newborns: gender identity/role differentiation in genetic males affected by abnormal sex differentiation.

    Minerva pediatrica·2004
    Same author

    Female phenotype at birth and postnatal masculinization, during the first months of life, associated with transient 5 alpha-reductase 2 deficiency in a preterm infant. A timing defect syndrome?

    Minerva pediatrica·2004
    Same author

    Congenital micropenis: long-term medical, surgical and psychosexual follow-up of individuals raised male or female.

    Hormone research·2002
    Same author

    Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Growth, development, and therapeutic considerations.

    Endocrinology and metabolism clinics of North America·2001
    Same author

    Human sex differentiation: from transcription factors to gender.

    Hormone research·2000

    Long-term estrogen therapy, especially with high cumulative doses (≥2500 mg) over 4.2 years, is linked to endometrial abnormalities in hypogonadal patients. Progestogens did not prevent these changes.

    Area of Science:

    • Reproductive Endocrinology
    • Gynecologic Pathology

    Background:

    • Hypogonadal patients often undergo hormone replacement therapy.
    • Estrogen-progestogen therapy is a common treatment regimen.

    Purpose of the Study:

    • To investigate the relationship between estrogen-progestogen therapy and endometrial abnormalities in hypogonadal patients.
    • To identify risk factors for endometrial changes during hormone therapy.

    Main Methods:

    • Endometrial biopsies were analyzed from 46 hypogonadal patients undergoing estrogen-progestogen therapy.
    • Correlation analysis was performed between cumulative estrogen dose, duration of treatment, and endometrial biopsy outcomes.

    Main Results:

    • Endometrial abnormalities were observed exclusively in patients with a total lifetime conjugated estrogen dose ≥2500 mg and treatment duration >4.2 years.
    Keywords:
    BiologyCancerClinical ResearchContraceptionContraceptive AgentsContraceptive Agents, FemaleContraceptive Agents, ProgestinDiethylstilbestrolDiseasesEndocrine SystemEndometrial CancerEstrogenic Substances, ConjugatedEstrogensFamily PlanningHormonesMedroxyprogesterone AcetateNeoplasmsNorethindronePhysiologyResearch Methodology

    Related Experiment Videos

  • Biopsy outcomes significantly correlated with estrogen dose at biopsy (P<0.01) and total lifetime dose (P<0.05).
  • Progestogens did not offer protection against endometrial abnormalities; no abnormal bleeding was noted.

    • Conclusions:

    • High cumulative estrogen doses and prolonged treatment duration are critical factors for endometrial abnormalities in hypogonadal women.
    • Current progestogen use in this regimen does not mitigate the risk of endometrial changes.
    • Endometrial abnormalities may occur asymptomatically without abnormal vaginal bleeding.